PMID- 25660387
OWN - NLM
STAT- MEDLINE
DCOM- 20150626
LR  - 20220330
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 159
IP  - 5
DP  - 2015 May
TI  - Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness 
      macular holes.
PG  - 861-7.e2
LID - S0002-9394(15)00063-X [pii]
LID - 10.1016/j.ajo.2015.01.034 [doi]
AB  - PURPOSE: To analyze a single center's experiences with ocriplasmin on 
      vitreomacular traction (VMT) and the rate of VMT release, full-thickness macular 
      hole (full-thickness MH) closure, and best-corrected visual acuity (BCVA) 
      changes. DESIGN: Retrospective interventional case series. METHODS: Single-center 
      study of 58 eyes of 56 patients who received intravitreal ocriplasmin for VMT 
      with or without full-thickness MH. VMT release, full-thickness MH closure, visual 
      acuity changes, and anatomic characteristics on spectral-domain optical coherence 
      tomography (SD OCT) were analyzed. RESULTS: VMT resolved in 29 of 58 eyes (50%) 
      and nonsurgical closure of full-thickness MH was achieved in 4 of 15 eyes (27%). 
      Mean logMAR BCVA among all treated eyes improved from 0.51 (20/65) at baseline to 
      0.36 (20/46) at final follow-up (P = .0018) with mean follow-up of 8.7 months. 
      When compared to eyes without VMT release, eyes with successful vitreomacular 
      release had a better pretreatment BCVA (20/48 vs 20/89, P = .004) and final 
      follow-up BCVA (20/31 vs 20/68, P = .0001). Improvement in BCVA was significant 
      in eyes with VMT release (P = .0001). Transient ellipsoid zone changes were noted 
      in 26% of treated eyes (n = 15), of which 14 had successful VMT release. 
      Transient subfoveal fluid accumulation was noted in all these patients with 
      vitreomacular release. Mean time to resolution of ellipsoid zone changes was 
      within 38 days. CONCLUSION: In clinical practice, intravitreal injection of 
      ocriplasmin achieved VMT release in approximately one half of treated eyes, with 
      a 27% closure rate for full-thickness MH. Transient ellipsoid changes were 
      evident in 26% of treated eyes, more common in eyes with successful VMT release.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Sharma, Priya
AU  - Sharma P
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Juhn, Alexander
AU  - Juhn A
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Houston, Samuel K
AU  - Houston SK
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Fineman, Mitchell
AU  - Fineman M
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Chiang, Allen
AU  - Chiang A
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Ho, Allen
AU  - Ho A
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Regillo, Carl
AU  - Regillo C
AD  - Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, 
      Pennsylvania. Electronic address: cregillo@aol.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150204
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Peptide Fragments)
RN  - 7V6HE3DM5A (microplasmin)
RN  - EC 3.4.21.7 (Fibrinolysin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Extracellular Matrix/*drug effects/metabolism
MH  - Extracellular Matrix Proteins/metabolism
MH  - Female
MH  - Fibrinolysin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Retinal Perforations/*drug therapy/metabolism/physiopathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity/physiology
EDAT- 2015/02/11 06:00
MHDA- 2015/06/27 06:00
CRDT- 2015/02/10 06:00
PHST- 2014/11/26 00:00 [received]
PHST- 2015/01/28 00:00 [revised]
PHST- 2015/01/28 00:00 [accepted]
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2015/06/27 06:00 [medline]
AID - S0002-9394(15)00063-X [pii]
AID - 10.1016/j.ajo.2015.01.034 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2015 May;159(5):861-7.e2. doi: 10.1016/j.ajo.2015.01.034. Epub 
      2015 Feb 4.